Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES

Reference is made to the announcement of Aceso Life Science Group Limited (the "**Company**") dated 15 July 2025 in relation to the Disposal, which constitutes a major transaction of the Company under Chapter 14 of the Listing Rules (the "**Announcement**"). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

According to Rule 14.41(a) of the Listing Rules, the Company is required to despatch a circular to the Shareholders within 15 business days after publication of the Announcement, i.e. on or before 5 August 2025.

The Company is still in the course of preparing the circular. Since more time is required for the Company to incorporate the relevant information in the circular, including but not limited to indebtedness statement and working capital statement, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the "**Waiver**").

On 5 August 2025, the Stock Exchange has granted the Waiver to the Company on the basis that the Company will despatch the circular to the Shareholders on or before 26 August 2025. The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 7 August 2025

As at the date of this announcement, the board of Directors comprises two executive Directors, namely Dr. Zhiliang Ou, J. P. (Australia) and Mr. Fok Chi Tak; one non-executive Director, namely Ms. Jiang Yang; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.